Literature DB >> 33874858

Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease.

Magdalena K Stoeva1, Jeewon Garcia-So1, Nicholas Justice1, Julia Myers1, Surabhi Tyagi1, Madeleine Nemchek1, Paul J McMurdie1, Orville Kolterman1, John Eid1.   

Abstract

Clostridium butyricum is a butyrate-producing human gut symbiont that has been safely used as a probiotic for decades. C. butyricum strains have been investigated for potential protective or ameliorative effects in a wide range of human diseases, including gut-acquired infection, intestinal injury, irritable bowel syndrome, inflammatory bowel disease, neurodegenerative disease, metabolic disease, and colorectal cancer. In this review we summarize the studies on C. butyricum supplementation with special attention to proposed mechanisms for the associated health benefits and the supporting experimental evidence. These mechanisms center on molecular signals (especially butyrate) as well as immunological signals in the digestive system that cascade well beyond the gut to the liver, adipose tissue, brain, and more. The safety of probiotic C. butyricum strains appears well-established. We identify areas where additional human randomized controlled trials would provide valuable further data related to the strains' utility as an intervention.

Entities:  

Keywords:  Clostridium butyricum; butyrate; cancer; immunity; inflammation; intestinal barrier; irritable bowel syndrome; metabolic disease; neurodegeneration; short chain fatty acid

Mesh:

Substances:

Year:  2021        PMID: 33874858      PMCID: PMC8078720          DOI: 10.1080/19490976.2021.1907272

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  130 in total

1.  Clostridium butyricum activates TLR2-mediated MyD88-independent signaling pathway in HT-29 cells.

Authors:  Quanxin Gao; Lili Qi; Tianxing Wu; Jinbo Wang
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

Review 2.  A catch-22: Interleukin-22 and cancer.

Authors:  Pedro Hernandez; Konrad Gronke; Andreas Diefenbach
Journal:  Eur J Immunol       Date:  2018-01       Impact factor: 5.532

3.  Sodium Butyrate Attenuates Diarrhea in Weaned Piglets and Promotes Tight Junction Protein Expression in Colon in a GPR109A-Dependent Manner.

Authors:  Wenqian Feng; Yancheng Wu; Guangxin Chen; Shoupeng Fu; Bai Li; Bingxu Huang; Dali Wang; Wei Wang; Juxiong Liu
Journal:  Cell Physiol Biochem       Date:  2018-06-27

4.  Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo.

Authors:  K Isa; K Oka; N Beauchamp; M Sato; K Wada; K Ohtani; S Nakanishi; E McCartney; M Tanaka; T Shimizu; S Kamiya; C Kruger; M Takahashi
Journal:  Hum Exp Toxicol       Date:  2015-10-05       Impact factor: 2.903

5.  [Antagonistic interaction between Clostridium butyricum and enterohemorrhagic Escherichia coli O157:H7].

Authors:  M Takahashi; H Taguchi; H Yamaguchi; T Osaki; R Sakazaki; S Kamiya
Journal:  Kansenshogaku Zasshi       Date:  1999-01

6.  The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice.

Authors:  Motomichi Takahashi; Haruhiko Taguchi; Hiroyuki Yamaguchi; Takako Osaki; Akio Komatsu; Shigeru Kamiya
Journal:  FEMS Immunol Med Microbiol       Date:  2004-07-01

7.  Clostridium butyricum attenuates cerebral ischemia/reperfusion injury in diabetic mice via modulation of gut microbiota.

Authors:  Jing Sun; Fangyan Wang; Zongxin Ling; Xichong Yu; Wenqian Chen; Haixiao Li; Jiangtao Jin; Mengqi Pang; Huiqing Zhang; Junjie Yu; Jiaming Liu
Journal:  Brain Res       Date:  2016-03-29       Impact factor: 3.252

8.  Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI.

Authors:  Hiromi Seki; Masaaki Shiohara; Tadao Matsumura; Natsuki Miyagawa; Mamoru Tanaka; Atsushi Komiyama; Susumu Kurata
Journal:  Pediatr Int       Date:  2003-02       Impact factor: 1.524

9.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.

Authors:  Gal Markel; Ben Boursi; Erez N Baruch; Ilan Youngster; Guy Ben-Betzalel; Rona Ortenberg; Adi Lahat; Lior Katz; Katerina Adler; Daniela Dick-Necula; Stephen Raskin; Naamah Bloch; Daniil Rotin; Liat Anafi; Camila Avivi; Jenny Melnichenko; Yael Steinberg-Silman; Ronac Mamtani; Hagit Harati; Nethanel Asher; Ronnie Shapira-Frommer; Tal Brosh-Nissimov; Yael Eshet; Shira Ben-Simon; Oren Ziv; Md Abdul Wadud Khan; Moran Amit; Nadim J Ajami; Iris Barshack; Jacob Schachter; Jennifer A Wargo; Omry Koren
Journal:  Science       Date:  2020-12-10       Impact factor: 47.728

10.  Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine.

Authors:  Ivaylo I Ivanov; Rosa de Llanos Frutos; Nicolas Manel; Keiji Yoshinaga; Daniel B Rifkin; R Balfour Sartor; B Brett Finlay; Dan R Littman
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

View more
  28 in total

1.  A probiotic supplement boosts response to cancer immunotherapy.

Authors:  Lisa Derosa; Laurence Zitvogel
Journal:  Nat Med       Date:  2022-04       Impact factor: 53.440

Review 2.  New Advances in Improving Bone Health Based on Specific Gut Microbiota.

Authors:  Qihui Yan; Liping Cai; Weiying Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-07-04       Impact factor: 6.073

3.  Gut Steroids and Microbiota: Effect of Gonadectomy and Sex.

Authors:  Silvia Diviccaro; Jamie A FitzGerald; Lucia Cioffi; Eva Falvo; Fiona Crispie; Paul D Cotter; Siobhain M O'Mahony; Silvia Giatti; Donatella Caruso; Roberto Cosimo Melcangi
Journal:  Biomolecules       Date:  2022-05-31

4.  Role of mucus-bacteria interactions in Enterotoxigenic Escherichia coli (ETEC) H10407 virulence and interplay with human microbiome.

Authors:  Lucie Etienne-Mesmin; Stéphanie Blanquet-Diot; Thomas Sauvaitre; Josefien Van Landuyt; Claude Durif; Charlène Roussel; Adeline Sivignon; Sandrine Chalancon; Ophélie Uriot; Florence Van Herreweghen; Tom Van de Wiele
Journal:  NPJ Biofilms Microbiomes       Date:  2022-10-20       Impact factor: 8.462

5.  Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway.

Authors:  Mingyao Zhou; Wei Yuan; Bing Yang; Wei Pei; Jie Ma; Qiang Feng
Journal:  Ann Transl Med       Date:  2022-04

6.  A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans.

Authors:  Heike Tom Dieck; Christiane Schön; Tanja Wagner; Helga Carola Pankoke; Monika Fluegel; Bodo Speckmann
Journal:  Nutrients       Date:  2021-12-29       Impact factor: 5.717

7.  Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes.

Authors:  Paul J McMurdie; Magdalena K Stoeva; Nicholas Justice; Madeleine Nemchek; Christian M K Sieber; Surabhi Tyagi; Jessica Gines; Connor T Skennerton; Michael Souza; Orville Kolterman; John Eid
Journal:  BMC Microbiol       Date:  2022-01-08       Impact factor: 3.605

Review 8.  Effect of Clostridium butyricum on Gastrointestinal Infections.

Authors:  Tadashi Ariyoshi; Mao Hagihara; Motomichi Takahashi; Hiroshige Mikamo
Journal:  Biomedicines       Date:  2022-02-18

9.  Living Bacteria-Based Immuno-Photodynamic Therapy: Metabolic Labeling of Clostridium butyricum for Eradicating Malignant Melanoma.

Authors:  Leilei Shi; Xiaoxiao Liu; Yuzhen Li; Sha Li; Wenbo Wu; Xihui Gao; Bin Liu
Journal:  Adv Sci (Weinh)       Date:  2022-03-11       Impact factor: 17.521

Review 10.  Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases.

Authors:  Haokun Shen; Zitong Zhao; Zengjue Zhao; Yuyi Chen; Linghua Zhang
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.